



PRESS RELEASE

For Immediate Release

12 December 2007

SYNAIRGEN PLC (‘Synairgen’ or the ‘Company’)

Collaboration signed to advance Growth Factor Programme

Synairgen, the company developing novel therapies for asthma and COPD, today announces that it has entered into a collaboration with Professor David Bassett of Wayne State University, Michigan, USA, to provide further evidence on the efficacy of growth factors in a validated preclinical model.

David Bassett is Professor of Occupational and Environmental Health at Wayne State University School of Medicine and has more than 30 years’ experience in the respiratory area. He has published extensively in the field of pulmonary and inhalation toxicology. His role in the collaboration will be to evaluate the effectiveness of Synairgen’s growth factor against the asthma-like symptoms that develop in well-validated preclinical models developed at Wayne State University. The results of the collaboration are expected by mid 2008.

Richard Marsden, Synairgen’s Managing Director, said, “David Bassett has extensively researched the effects of allergen on lung inflammation and lung function. Demonstration that our growth factor can have a positive outcome against clinically relevant symptoms that develop in his models, together with our established data generated in human cells from asthmatics, will significantly increase the confidence in the likelihood of success in the clinical development programme.”

-Ends-

For further information, please contact:

Synairgen

Richard Marsden, Managing Director
John Ward, Finance Director

Tel: + 44 (0) 2380 512 800

The Hogarth Partnership

Melanie Toyne-Sewell
Simon Hockridge

Tel: + 44 (0) 20 7357 9477

Notes to Editors

About Synairgen

Synairgen is a drug discovery company founded by Professors Stephen Holgate, Donna Davies and Ratko Djukanovic, focused on identifying and out-licensing new pharmaceutical products which address the underlying causes of asthma and chronic obstructive pulmonary disease. Synairgen is listed on AIM (LSE: SNG).

For more information about Synairgen, please see www.synairgen.com.

About Synairgen's Growth Factor Programme

Synairgen's researchers have found that the cells which line the airways (the epithelium) of asthmatics do not form a robust barrier. This defect in barrier function may be a key contributor to asthma susceptibility, enabling known triggers of asthma, such as allergens, pollutants and viruses, to penetrate through the epithelium to the underlying tissue. Using asthmatic epithelial cells from its biobank of human tissue, Synairgen has developed a modified growth factor that can restore barrier function.

About Prof David Bassett

David Bassett has published extensively in the field of pulmonary and inhalation toxicology and is currently examining the biochemical and patho-physiological determinants associated with the development of inflammatory diseases of the lung resulting from exposures to allergens and other airborne substances found in workplace, home and ambient environments.

For a fuller biography of Prof Bassett, please see www.cphs.wayne.edu/research/faculty.php